STAT3 PHOSPHOPEPTIDE INHIBITOR - 10mg/30mg

STRUCTURE

Sequence: Ac-Gly-{p-Tyr}-Leu-Pro-Gln-Thr-Val-NH2  

Molecular Formula: C38H60N9O14P

CAS number: 1349616-70-1  

Peptide Purity: greater than 98%

Other details: No TFA Salt

Storage: Lyophilized peptide must be stored at -20°C and peptide solution at +4°C.

DESCRIPTION

STAT3 (Signal Transducer and Activator of Transcription 3) is a crucial transcription factor involved in cell proliferation, survival, immune modulation, and inflammation. In many cancers, including multiple myeloma, leukemia, glioblastoma, breast, and lung cancer, STAT3 is abnormally activated, driving tumor progression, drug resistance, and immune evasion.

The STAT3 Inhibitor Peptide functions as a competitive inhibitor by binding to the SH2 domain of STAT3, preventing its phosphorylation and dimerization. This disrupts oncogenic signaling, leading to reduced tumor growth, increased apoptosis, and enhanced therapeutic sensitivity.

Benefits of STAT3 Inhibition

• Inhibits Tumor Growth – Blocks STAT3-driven oncogenic pathways to slow cancer progression.
• Overcomes Drug Resistance – Disrupts STAT3-mediated resistance mechanisms in various cancers.
• Promotes Apoptosis – Encourages programmed cell death in cancer cells.
• Anti-Inflammatory & Immune Modulation – Reduces inflammatory responses that contribute to tumor growth.

STAT3 Inhibition in Cancer Treatment

Multiple Myeloma Treatment: Multiple myeloma (MM) is associated with persistent STAT3 activation, contributing to uncontrolled proliferation, immune evasion, and chemotherapy resistance. STAT3 inhibition helps by:

• Blocking STAT3 signaling, leading to tumor suppression.
• Restoring chemotherapy sensitivity, enhancing the efficacy of standard treatments.
• Reducing myeloma-associated inflammation, limiting disease progression.

Targeting STAT3 in multiple myeloma could significantly improve patient outcomes, particularly in relapsed or treatment-resistant cases.

Leukemia Treatment: STAT3 plays a pivotal role in acute and chronic leukemias, promoting self-renewal of leukemia stem cells, drug resistance, and immune evasion. The STAT3 Inhibitor Peptide may be beneficial in:

• Acute Myeloid Leukemia (AML) – Blocking STAT3 reduces leukemia cell proliferation and induces apoptosis.
• Chronic Lymphocytic Leukemia (CLL) – Inhibiting STAT3 enhances sensitivity to targeted therapies.
• Acute Lymphoblastic Leukemia (ALL) – Disrupting STAT3 activity decreases leukemia stem cell survival.

STAT3 inhibition could be a promising strategy in leukemia treatment, especially for relapsed or refractory cases.

Glioblastoma Treatment: Glioblastoma multiforme (GBM) is one of the most aggressive brain tumors, where STAT3 overactivation contributes to tumor growth, invasion, and resistance to standard therapies. The STAT3 Inhibitor Peptide offers therapeutic potential by:

• Inhibiting glioblastoma stem cells, which drive tumor recurrence.
• Reducing angiogenesis, limiting tumor blood supply.
• Increasing radiosensitivity, making radiation therapy more effective.
• Suppressing tumor invasion, slowing glioblastoma progression.

STAT3 inhibition is being explored as an adjunct therapy to improve survival rates in glioblastoma patients.

Breast and Lung Cancer Treatment: STAT3 is frequently hyperactivated in breast and lung cancers, promoting tumor growth, metastasis, and chemotherapy resistance. Inhibition of STAT3 can:

• Reduce metastasis, limiting tumor spread.
• Enhance the efficacy of chemotherapy and immunotherapy.
• Lower tumor-associated inflammation, improving immune system response.
• Induce apoptosis in STAT3-dependent cancer cells.

STAT3 inhibitors show promise in aggressive, triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), where resistance to therapy is a major challenge.

Summary:

The Role of STAT3 Inhibition in Cancer Therapy

The STAT3 Inhibitor Peptide represents a novel approach to cancer treatment, offering potential benefits for:

• Multiple Myeloma – Blocks tumor growth, enhances chemotherapy sensitivity.
• Leukemia – Disrupts leukemia stem cell survival and drug resistance.
• Glioblastoma – Reduces tumor invasion, angiogenesis, and recurrence.
• Breast & Lung Cancer – Lowers metastasis and improves response to therapy.

This peptide could be valuable as a standalone or adjunct therapy in cancers where STAT3 is a critical oncogenic driver.

DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.